ClinicalTrials.gg
CompletedNCT02168205Updated Nov 15, 2018

Food Effect and CYP1A2 Induction Study in Healthy Subjects

A Phase 1 interventional study of Pomalidomide and Caffeine in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-15.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This study will evaluate the effect of food and smoking on healthy older subjects taking pomalidomide.

Read the detailed description

This study will be conducted in two parts. Parts 1 and 2 may be conducted in parallel and subjects are only allowed to participate in one part.

In Part 1, subjects will be randomly assigned to receive a single oral dose of 4 mg pomalidomide on Day 1 under fed (standard high fat breakfast) or fasted conditions. After a washout period of at least 3 and no more than 7 days, subjects will receive a single oral dose of 4 mg pomalidomide under the opposite condition to what they received in the first period.

In Part 2, healthy male smoker subjects must smoke approximately 20 cigarettes per day for a total of 10 days. Non-smokers will neither smoke nor be in the presence of smokers. All subjects will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, subjects will receive a single oral dose of 4 mg pomalidomide.

For both Parts 1 and 2, serial blood samples will be collected for determination of plasma pomalidomide concentrations.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteer
  • Pharmacokinetics
  • Pomalyst
  • Pomalidomide
  • Food effect
  • smoker
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: 1.Must understand and voluntarily sign a written prior to any study-related procedures being performed.

    2.Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.

    3.Must be male or * women of any race between ≥61 to ≤85 years of age (inclusive) at the time of signing the Informed Consent, and in good health as determined by a physical exam, clinical laboratory safety test results, vital signs, and 12 lead .

    * =Naturally postmenopausal for at least 24 consecutive months (ie, who has not had menses at any time in the preceding 24 consecutive months) 4.Subjects must be a non smoker. 5.Clinical laboratory tests must be within normal limits or acceptable to the Principal Investigator (PI).

    6.Must have a normal or clinically acceptable 12-lead Electrocardiogram. 7.Must be afebrile (febrile is defined as ≥ 38.0ºC or 100.4 Fahrenheit), with supine systolic blood pressure (BP): 90 to 150 mmHg, supine diastolic blood pressure: 60 to 95 mmHg, and pulse rate: 40 to 110 bpm and controlled on medications if they are indicated (especially for blood pressure).

    1. If a subject has a diagnosis of hypertension, the range for BP and pulse rate will be the one that is considered well controlled on medication.

      8.Must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female that can get pregnant while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.

      * = True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of 9.Must agree to refrain from donating sperm or semen while participating in this study and for at least 28 days following the last dose of study drug.

      10.Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days following the last dose of study drug.

      11.Must agree to comply with the conditions described in the counseling document (part of the pomalidomide Pregnancy Prevention Risk Management Plan.

      Part 2

      1. Must understand and voluntarily sign a written informed consent prior to any study-related procedures being performed.
      2. Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
      3. Must be male of any race between 40 to 80 years of age (inclusive) at the time of signing the Informed Consent, and in good health as determined by a physical exam, clinical laboratory safety test results, vital signs, and 12 lead electrocardiogram.
      4. Cohort A subjects (smokers) must have a history of smoking for >5 years and currently smoke ≥1 pack (20-25) cigarettes per day; and urine cotinine level at screening and baseline (Day -1) indicate subject is heavy smoker.
      5. Cohort B subjects (non-smokers) must have not smoked for >5 years (Cohort B).
      6. Clinical laboratory tests must be within normal limits or acceptable to the Principal Investigator.
      7. Must have a normal or clinically acceptable 12-lead Electrocardiogram, with a value ≤ 450 msec.
      8. Must be afebrile (febrile is defined as ≥ 38.0ºC or 100.4 Fahrenheit), with supine systolic blood pressure (BP): 90 to 150 mmHg, supine diastolic blood pressure: 60 to 95 mmHg, and pulse rate: 40 to 110 bpm and controlled on medications if they are indicated (especially for blood pressure).
      9. Must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female that can get pregnant while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.
      10. Must agree to refrain from donating sperm or semen while participating in this study and for at least 28 days following the last dose of study drug.
      11. Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days following the last dose of study drug.
      12. Must agree to comply with the conditions described in the counseling document (part of the pomalidomide Pregnancy Prevention Risk Management Plan.

Exclusion criteria

Exclusion Criteria:

  • Both Parts:

    1. History of any and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, known to a member of the class of drugs that can modulate the immune system, or other major disorders.

      1. Subjects with well-controlled hypertension, hyperlipidemia, gout, asthma/, hypothyroidism and other common age-related disorders, requiring treatment and being well-controlled on concomitant prescription medication(s) will be eligible for inclusion in the study.
      2. Subjects with diabetes, significant gastrointestinal diseases or hematologic disorders should not be included in the study.
    2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
    3. Used any prescribed systemic or topical medication within 30 days of the first dose administration, unless these medications are chronically administered and Sponsor agreement is obtained.
    4. Used any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration, unless these medications are chronically administered and Sponsor agreement is obtained.
    5. Has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion, e.g., bariatric procedure.
    6. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
    7. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual within 2 years before dosing, or positive drug screening test reflecting consumption of illicit drugs.
    8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before dosing, or positive alcohol screen.
    9. Known to have serum hepatitis or known to be a carrier of the surface antigen, or antibody, or have a positive result to the test for antibodies at Screening.
    10. Exposed to an drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
    11. Received vaccination (excluding seasonal flu vaccination) within 90 days of the study drug administration.
    12. Subjects who are part of the staff personnel or family members of the investigational study staff.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    4 mg Pomalidomide - Fed

    On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.

    Drug: Pomalidomide

  • Experimental
    4 mg Pomalidomide - Fasted

    On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions

    Drug: Pomalidomide

  • Experimental
    4 mg Pomalidomide + caffeine - Non-smoking

    Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.

    Drug: Pomalidomide · Other: Caffeine

  • Experimental
    4 mg Pomalidomide + caffeine - Smoking

    Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.

    Drug: Pomalidomide · Other: Caffeine · Other: Tobacco

Interventions

  • Capsules

  • OtherCaffeine

    Capsules

  • OtherTobacco

    Cigarettes

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax

    Maximum observed concentration in plasma

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

  2. Pharmacokinetics - Tmax

    Time to maximum observed concentration in plasma

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

  3. Pharmacokinetics - AUC

    Area under the plasma concentration-time curve

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

  4. Pharmacokinetics - T1/2

    Terminal half-life

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

  5. Pharmacokinetics - Vz/f

    Apparent volume of distribution

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

  6. Pharmacokinetics - CL/F

    Apparent total body clearance

    Time frame: Up to 8 days for Part 1; up to 10 days for Part 2

Secondary outcomes

  1. Adverse events

    Number of participants with adverse events

    Time frame: Approximately 1 month

07

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Sep 2014, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2014
First posted
Jun 20, 2014
StartActual
May 30, 2014
Primary completionActual
Sep 19, 2014
CompletionActual
Sep 19, 2014
Last update
Nov 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02168205
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 20, 2014
Start date
May 30, 2014
Primary completion
Sep 19, 2014
Completion
Sep 19, 2014
Last update
Nov 15, 2018

Study contacts

Edward O'Mara, MD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion